SFS
REGN icon

Stiles Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Stiles Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Sell
3,650
-361
-9% -$276K 0.86% 39
2025
Q4 		$3.1M Sell
4,011
-342
-8% -$232K 0.95% 28
2025
Q3 		$2.45M Sell
4,353
-5
-0.1% -$2.83K 0.77% 43
2025
Q2 		$2.29M Buy
4,358
+262
+6% +$146K 0.79% 46
2025
Q1 		$2.6M Buy
4,096
+200
+5% +$138K 1% 29
2024
Q4 		$2.77M Buy
3,896
+464
+14% +$389K 1% 29
2024
Q3 		$3.61M Buy
3,432
+89
+3% +$99K 1.27% 17
2024
Q2 		$3.51M Buy
3,343
+64
+2% +$62K 1.35% 16
2024
Q1 		$3.16M Buy
3,279
+246
+8% +$234K 1.26% 18
2023
Q4 		$2.66M Buy
3,033
+334
+12% +$275K 1.21% 25
2023
Q3 		$2.22M Buy
2,699
+753
+39% +$592K 1.15% 21
2023
Q2 		$1.4M Buy
1,946
+571
+42% +$440K 0.69% 48
2023
Q1 		$1.13M Buy
1,375
+385
+39% +$290K 0.61% 54
2022
Q4 		$714K Buy
+990
New +$730K 0.41% 71

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stiles Financial Services's REGN Position: Q1 2026 in Review

Stiles Financial Services reduced its Regeneron Pharmaceuticals (REGN) stake by 9% in Q1 2026, selling an estimated $276K and leaving 3,650 shares worth $2.82M. The position accounts for 0.86% of the portfolio, ranked #39.

Stiles Financial Services first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.61M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Stiles Financial Services held 3,650 shares of Regeneron Pharmaceuticals worth $2.82M as of Q1 2026.
  • Stiles Financial Services sold 361 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $276K.
  • Regeneron Pharmaceuticals made up 0.86% of Stiles Financial Services's portfolio in Q1 2026, its #39 holding.
  • Stiles Financial Services first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Stiles Financial Services's Regeneron Pharmaceuticals position peaked at $3.61M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Stiles Financial Services's 13F filing for Q1 2026, filed 30 Apr 2026.